LAB 03 FZC private label minoxidil hair growth serum — 2% and 5% topical minoxidil for androgenetic alopecia, manufactured in Sharjah UAE with full regulatory documentation

Minoxidil Hair Growth Serum — Private Label UAE

Additional information

Topical minoxidil at 2% and 5% concentrations — the most clinically validated hair growth active available, FDA-approved for over 30 years, with the most extensive peer-reviewed efficacy data of any hair loss treatment. Formulated as a dropper serum with a penetration-enhancing vehicle system for maximum follicle delivery. Full regulatory documentation for UAE, GCC, EU, and USA markets provided.

MOQ

Flexible

Turnaround

2-4 weeks

Quote

Within 24-48 hrs

Export

UAE · GCC · EU · USA

Request a Quote
Chat on Whatsapp

Free Formulation on orders above 20,000 AED ($5,500). T&C apply.

GMP-ISO 22716

Certified

ISO 14001

Environmental

Made in UAE

Sharjah

GCC Compliant

Export ready

About this formulation

Minoxidil is the most clinically validated hair growth active available — FDA-approved since 1988 for androgenetic alopecia, with over three decades of peer-reviewed efficacy and safety data across millions of users. It remains the reference treatment against which every emerging hair growth active (caffeine, rosemary, saw palmetto, PDRN) is benchmarked in clinical comparison studies. For brands targeting clinics, dermatology practices, and pharmacy retail in markets where minoxidil is classified as an OTC drug or cosmetic ingredient, a private label minoxidil serum is the commercially strongest and most clinically credible hair loss treatment product available.

LAB 03 FZC manufactures topical minoxidil at 2% and 5% concentrations in a penetration-optimised vehicle system designed to maximise follicle delivery. The standard vehicle is a propylene glycol-based hydroalcoholic solution — the same vehicle system used in the original FDA-approved formulations and with the most extensive safety and efficacy data. A propylene glycol-free variant is available for the clinically significant proportion of users (approximately 5–7%) who experience scalp irritation from propylene glycol. A foam vehicle is available as a premium alternative that eliminates the propylene glycol concern entirely while improving cosmetic experience and compliance. The dropper applicator tip delivers precise, section-by-section scalp application at the therapeutic volume (1ml per application, twice daily).

The minoxidil serum is architecturally different from the LAB 03 FZC Hair Growth Scalp Serum range (which uses cosmetic-grade actives including caffeine, rosemary, PDRN, and Capixyl). Minoxidil is a pharmaceutical active — it has a different mechanism of action (potassium channel opening and direct vasodilation rather than DHT inhibition), a different regulatory classification (OTC drug, quasi-drug, or cosmetic depending on market), and a different commercial distribution channel (pharmacy, clinic prescription, or online pharmacy rather than beauty retail). The two product ranges are complementary rather than competing — many clinical protocols use oral or topical minoxidil as the primary treatment with the cosmetic serum as a complementary home care protocol.

Key benefits

  • Most clinically validated hair growth active — FDA-approved since 1988; 30+ years of peer-reviewed data; the gold standard against which all other treatments are compared
  • Two concentrations — 2% (women and men; gentler; fewer side effects) and 5% (men; stronger efficacy; faster results)
  • Three vehicle options — standard propylene glycol solution, PG-free solution, and foam — addressing the most common compliance barrier (scalp irritation from PG)
  • Penetration-optimised formula — vehicle system designed for maximum follicle delivery at the 1ml twice-daily therapeutic dose
  • 84% response rate at 5% concentration in pivotal clinical trials — the highest documented response rate of any OTC hair growth treatment

What's Inside?

Full INCI list available once the formula and sample are approved. Formula can be adjusted to include or substitute any active

Make it yours — full customisation available

Formula customisation

Concentration: 2% (women and men) / 5% (men; off-label women) Vehicle: standard PG solution / PG-free solution / foam Complementary actives: caffeine (1–2%) as supplementary anagen extender; biotin; niacinamide Fragrance: unscented standard (mandatory for all vehicles) — clinical formulation Preservative: standard antimicrobial system appropriate for market requirements pH: 3.5–6.0 — adjusted for maximum minoxidil stability and scalp compatibility

Packaging Options

Dropper bottle with scalp applicator nozzle (solution — standard) Pressurised foam canister (foam vehicle — premium MOQ applies) Sizes: 30ml · 60ml · 100ml (solution) · 60g (foam) Material: HDPE or amber PET (solution) · aluminium canister (foam) Clinical white or matte packaging — pharmaceutical aesthetic Tamper-evident seal mandatory for all pharmaceutical markets

Label & Branding

Drug Facts panel (USA OTC) or pharmaceutical labelling per market requirements Active ingredient, inactive ingredient disclosure per regulatory requirement Concentration, dosing instructions, contraindications, warnings Market-specific claims per approved OTC monograph or registration Arabic + English for UAE/GCC markets Full regulatory dossier, stability data, and registration support provided

Add-on Avtices from our Bank

Ideal for your sector

Hotels & Resorts

Not Suitable

Spa & Wellness Centers

Not Suitable

Gyms & Fitness Clubs

Not Suitable

Clinics & Medical Centers

Treatment protocol anchor product Hair restoration clinics — offering PRP, mesotherapy, laser, and hair transplant services — need a clinic-branded topical minoxidil as the take-home maintenance product that continues follicle vasodilation between clinical sessions. Minoxidil's vasodilation mechanism directly complements injectable PRP (which stimulates growth factors) and laser low-level therapy (which improves follicle energy metabolism) — creating a multi-modality treatment protocol with the branded minoxidil serum at the home care centre. A 60ml bottle at the clinical dose (2ml daily) lasts 30 days — creating a reliable monthly reorder cycle from every active patient.

Retail Brands

The OTC hair loss category anchor In markets where minoxidil is classified as an OTC drug (USA, UK, Australia), a private label minoxidil product on pharmacy shelves competes directly with major branded products at a significantly lower consumer price point while maintaining the same active ingredient, concentration, and FDA-approved indication. For pharmacy chains and independent pharmacies developing own-brand OTC health products, minoxidil is one of the highest-value and highest-repurchase categories available. Full OTC drug registration support for USA (FDA OTC monograph) and UK (MHRA GSL) provided by LAB 03 FZC.

Who we also service

Our range covers corporate gifting programs · Airline amenity kits · Real estate developer handover gifts · Subscription box brands · Yacht & marine hospitality

Product Specifications

Product type Hair growth treatment — topical minoxidil solution / foam (pharmaceutical classification market-dependent)
Active ingredient Minoxidil — 2% w/v or 5% w/v
Indication Androgenetic alopecia (pattern hair loss) — male and female; telogen effluvium as off-label use
Vehicle options Standard PG solution (Propylene Glycol + Ethanol + Water) · PG-free solution (alternative penetration enhancers) · Foam (hydroalcoholic, PG-free)
Therapeutic dose 1ml twice daily (solution) · Half capful twice daily (foam) · Applied directly to scalp, not to hair
Contact time Minimum 4 hours before rinsing — 2× daily = 8–12 hours scalp exposure per 24 hours
Available sizes 30ml · 60ml · 100ml (solution) · 60g (foam)
Packaging HDPE or amber PET dropper bottle with scalp applicator nozzle (solution) · Aluminium pressurised canister (foam)
pH 3.5–6.0 (adjusted for maximum minoxidil stability)
Fragrance Unscented — clinical formulation standard
Shelf life 24 months (solution) · 18 months (foam) — stored at room temperature away from direct heat
GMP standard ISO 22716 GMP (cosmetic GMP) — pharmaceutical GMP upgrade available on request for markets requiring 21 CFR 211 compliance
Regulatory classification USA: OTC drug (FDA OTC monograph) · UAE/GCC: pharmaceutical registration required (MOHAP/SFDA) · EU: member state-specific · UK: GSL medicine (MHRA)
Documentation provided Full regulatory dossier, stability data, CPSR (where applicable), SFDA registration support, FDA OTC monograph documentation, MHRA GSL documentation
MOQ Flexible for solution · Higher MOQ for foam vehicle (pressurised canister tooling)
Production lead time 4–6 weeks from formula and regulatory approval (longer for markets requiring pre-market registration)
Certifications ISO 22716 GMP · ISO 14001 · SFDA · USFDA
Export markets Market-specific — regulatory consultation required before confirming export destination
HS Code 3004.90 — Medicaments for therapeutic or prophylactic uses (other) / 3305.90 where classified as cosmetic per market
Manufactured in Hamriyah Freezone Phase 2, Sharjah, United Arab Emirates

Ready to launch this body lotion under your brand?

Receive a no-obligation quote within 24–48 hours.

 
Request a Quote
Chat on Whatsapp

Frequently asked Questions

Can minoxidil be sold as a cosmetic in the UAE?

The regulatory status of topical minoxidil in the UAE depends on concentration and the specific regulatory pathway taken with MOHAP (Ministry of Health and Prevention). At very low concentrations, some jurisdictions have permitted minoxidil as a cosmetic ingredient under the cosmetic regulatory framework. At the therapeutic concentrations used for androgenetic alopecia (2% and 5%), the product is generally classified as a pharmaceutical or health product requiring MOHAP registration rather than a cosmetic registration under the cosmetic regulation. The regulatory pathway determines the permitted claims, the distribution channels, and the labelling requirements. LAB 03 FZC’s regulatory team works with each client to determine the correct registration pathway for their target market and intended distribution channel — the regulatory consultation is included at no charge with every minoxidil order inquiry. Do not proceed to order before completing the regulatory consultation, as the correct classification in your target market determines every aspect of the product’s packaging, labelling, and distribution.

Why does minoxidil cause initial hair shedding — and how should this be communicated to clients?

The initial shedding phase (weeks 2–6 of minoxidil use) is a pharmacological response, not a side effect indicating the product is causing harm. Minoxidil’s ability to induce telogen-to-anagen transition — pushing resting hair follicles back into active growth — causes the existing club hairs that were in telogen (the resting phase) to be shed simultaneously as the new anagen hairs begin growing underneath them. Think of it as the follicle clearing out the old before growing the new. The shed is directly proportional to the number of follicles responding to minoxidil — a heavier initial shed often correlates with a stronger ultimate response. The critical communication challenge is preventing premature discontinuation at the shed phase: studies consistently show that users who stop minoxidil during the initial shedding phase, believing the product is making their hair loss worse, never reach the growth phase that follows. Clinic consultation, label language, and patient information leaflets should all explicitly address the initial shedding phase — describing it as expected, temporary, and a sign of treatment response. This single communication point is the largest determinant of clinical outcome with topical minoxidil.

What is the difference between 2% and 5% minoxidil — which is better?

Both concentrations produce statistically significant hair regrowth versus placebo, with 5% producing faster and more pronounced results in men. In the pivotal comparative study, 5% minoxidil solution produced 45% more regrowth than 2% at 48 weeks in men, with a higher proportion of men rating themselves as improved. For men with androgenetic alopecia, 5% is the clinically preferred concentration. For women, 2% is the FDA-approved concentration — 5% is used off-label in women under medical guidance and has been shown in studies to be more effective but with a higher incidence of hypertrichosis (unwanted facial hair) from scalp run-off, particularly in the solution vehicle. The foam vehicle at 5% reduces this risk by collapsing on the warm scalp rather than running. For a private label brand targeting men, 5% is the standard recommendation. For women’s products, 2% is the regulatory standard with 5% foam as a clinically appropriate premium option. For a clinic serving both sexes, stocking both concentrations under a single branded range is the most commercially complete approach.

Can minoxidil and the cosmetic hair growth serum be used together?

Yes — and the combination is more effective than either treatment alone, because they act through completely separate mechanisms that address different aspects of the hair loss process. Minoxidil works through potassium channel opening and direct vasodilation — improving blood supply to the follicle bulb. The cosmetic hair growth serum (saw palmetto, Capixyl, azelaic acid) works through DHT inhibition and follicle protein synthesis support — addressing the hormonal miniaturisation mechanism. The two mechanisms are additive rather than competing: minoxidil supplies the follicle with resources (blood, nutrients, oxygen); the cosmetic serum prevents the DHT from causing progressive miniaturisation of the follicle that would reduce its capacity to use those resources. The recommended protocol is morning application of the cosmetic hair growth serum (leave-on, 30 minutes before styling) and evening application of minoxidil (leave-on overnight, minimum 4 hours). This separates the two application windows, prevents any interaction between the formulas, and ensures both products achieve their required scalp contact time independently.

Does minoxidil stop working if you stop using it?

Yes — and this is the most commercially significant compliance communication point for minoxidil products. Minoxidil’s efficacy is entirely dependent on continued use. The vasodilation and potassium channel opening that support follicle function cease when the drug is discontinued — within 3–6 months of stopping use, the follicles return to their pre-treatment miniaturisation trajectory driven by DHT activity. Hair density returns to approximately the pre-treatment baseline within 6–12 months of discontinuation. This means minoxidil is a long-term, indefinite treatment rather than a curative intervention — and this expectation must be clearly communicated on the label, in clinic consultation, and in any marketing materials. The indefinite-use requirement creates one of the most reliable recurring revenue models in the personal care category: a 60ml bottle at the 2ml daily dose lasts 30 days, creating a guaranteed monthly reorder cycle from every compliant user. The subscription or auto-refill model is the most commercially appropriate retail format for minoxidil products.

Related Products

Related products